Peptide-Guided Nanoparticles Deliver Gene Therapy to Cystic Fibrosis Lung Cells Through Mucus Barrier
A novel cell-penetrating peptide discovered via phage display improved mRNA lipid nanoparticle delivery to cystic fibrosis lung cells by up to 7.8-fold in vitro and 3.4-fold in mouse lungs.
Quick Facts
What This Study Found
A lead peptide identified from phage display against primary CF bronchial epithelial cells enhanced mRNA lipid nanoparticle delivery by 7.8-fold in vitro (primary human CF bronchial epithelia) and 3.4-fold in vivo (mouse lungs). The peptide facilitated specific uptake into lung epithelial cells relative to other cell types.
Key Numbers
Screening was performed against primary human bronchial epithelial cells from CF patients cultured at air-liquid interface for realistic conditions.
How They Did This
Phage display screening against primary human bronchial epithelial cells from CF patients cultured at air-liquid interface (producing mucus). Lead peptide incorporated into lipid nanoparticles carrying reporter mRNA (luciferase). Delivery efficiency measured in vitro on primary CF cells and in vivo in mouse lungs.
Why This Research Matters
Gene therapy could potentially cure cystic fibrosis by delivering correct copies of the CFTR gene, but getting the therapeutic cargo past airway mucus and into the right cells has been the main technical barrier. This peptide-guided approach represents a significant step toward making lung-targeted gene therapy for CF a reality.
The Bigger Picture
Cystic fibrosis is caused by a single gene defect, making it an ideal candidate for gene therapy. While mRNA and gene editing technologies have advanced rapidly, delivery to the lungs remains the biggest challenge. This peptide-targeting approach could be applicable not just to CF but to other lung diseases where targeted delivery through mucus barriers is needed.
What This Study Doesn't Tell Us
Mouse lungs differ significantly from human CF lungs in mucus composition and thickness. The fold-improvements, while significant, may need to be larger for therapeutic efficacy. Long-term safety of repeated peptide-nanoparticle administration to the lungs is unknown. The study used reporter mRNA, not therapeutic CFTR mRNA.
Questions This Raises
- ?Will the peptide-nanoparticle system deliver functional CFTR mRNA at levels sufficient to restore chloride channel function in CF airways?
- ?Does the peptide maintain its mucus-penetrating ability in severely affected CF lungs with much thicker mucus?
Trust & Context
- Key Stat:
- 7.8× delivery boost Peptide-decorated lipid nanoparticles delivered mRNA nearly 8 times more effectively to primary CF bronchial cells than unmodified nanoparticles, with 3.4-fold improvement confirmed in mouse lungs
- Evidence Grade:
- Preliminary evidence from a well-designed preclinical study using clinically relevant cell models (patient-derived CF cells at air-liquid interface) and in vivo mouse validation.
- Study Age:
- Published in 2024, representing cutting-edge research at the intersection of peptide science and gene therapy delivery.
- Original Title:
- Discovery of peptides for ligand-mediated delivery of mRNA lipid nanoparticles to cystic fibrosis lung epithelia.
- Published In:
- Molecular therapy. Nucleic acids, 35(4), 102375 (2024)
- Authors:
- Soto, Melissa R, Lewis, Mae M, Leal, Jasmim, Pan, Yuting, Mohanty, Rashmi P, Veyssi, Arian, Maier, Esther Y, Heiser, Brittany J, Ghosh, Debadyuti
- Database ID:
- RPEP-09311
Evidence Hierarchy
Frequently Asked Questions
What is phage display and how does it find useful peptides?
Phage display is a Nobel Prize-winning technique that uses viruses (phages) to display billions of different random peptide sequences on their surfaces. Scientists expose this library to target cells and identify which peptides bind best. It's like trying billions of keys to find the ones that fit a specific lock — in this case, finding peptides that can penetrate CF lung mucus and enter airway cells.
Could this approach cure cystic fibrosis?
It's a step in that direction but not a cure yet. The idea is to deliver correct copies of the CFTR gene (as mRNA) to lung cells using these peptide-guided nanoparticles. However, the effects of mRNA are temporary, so repeated doses would be needed. A true cure would require permanent gene correction, but effective delivery is a critical first step.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09311APA
Soto, Melissa R; Lewis, Mae M; Leal, Jasmim; Pan, Yuting; Mohanty, Rashmi P; Veyssi, Arian; Maier, Esther Y; Heiser, Brittany J; Ghosh, Debadyuti. (2024). Discovery of peptides for ligand-mediated delivery of mRNA lipid nanoparticles to cystic fibrosis lung epithelia.. Molecular therapy. Nucleic acids, 35(4), 102375. https://doi.org/10.1016/j.omtn.2024.102375
MLA
Soto, Melissa R, et al. "Discovery of peptides for ligand-mediated delivery of mRNA lipid nanoparticles to cystic fibrosis lung epithelia.." Molecular therapy. Nucleic acids, 2024. https://doi.org/10.1016/j.omtn.2024.102375
RethinkPeptides
RethinkPeptides Research Database. "Discovery of peptides for ligand-mediated delivery of mRNA l..." RPEP-09311. Retrieved from https://rethinkpeptides.com/research/soto-2024-discovery-of-peptides-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.